M&A Deal Summary

Athenex Acquires Kuur Therapeutics

On May 4, 2021, Athenex acquired life science company Kuur Therapeutics for 185M USD

Acquisition Highlights
  • This is Athenex’s 2nd transaction in the Life Science sector.
  • This is Athenex’s largest (disclosed) transaction.
  • This is Athenex’s 1st transaction in the United Kingdom.

M&A Deal Summary
Date 2021-05-04
Target Kuur Therapeutics
Sector Life Science
Buyer(s) Athenex
Deal Type Add-on Acquisition
Deal Value 185M USD

Target

Kuur Therapeutics

London, United Kingdom
Kuur Therapeutics is a developer, manufacturer, and marketer of cellular immunotherapy products for the treatment of cancer and infections. Kuur Therapeutics’s lead oncology product, baltaleucel-T, is aimed at a range of cancers associated with the oncogenic Epstein Barr virus (EBV), including non-Hodgkin lymphomas, Hodgkin lymphoma, and nasopharyngeal carcinoma. Kuur Therapeutics is based in London, United Kingdom.

Search 202,465 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Athenex

Buffalo, New York, United States
Category Company
Founded 2003
Sector Life Science
Employees652
Revenue 120M USD (2021)
DESCRIPTION

Athenex is a global biopharmaceutical company dedicated to discovery, development, and commercialization of novel therapies for the treatment of cancer. Athenex was founded in 2003 and is based in Buffalo, New york.

DEAL STATS #
Overall 2 of 2
Sector (Life Science) 2 of 2
Type (Add-on Acquisition) 2 of 2
Country (United Kingdom) 1 of 1
Year (2021) 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2014-09-09 QuaDPharma

New York, New York, United States

QuaDPharma specializing in pharmaceutical manufacturing, analytical, and support services to the pharmaceutical and biotech industries.

Buy -
Mergr

Product

Company

Legal